Special Issue "Staging and Pathology of Bladder Cancer"
Deadline for manuscript submissions: 15 July 2024 | Viewed by 1391
2. TMU Research Center of Urology and Kidney, Department of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
Interests: uro-oncology; bladder; urology; endocrinology; molecular biology; translation medicine
This Special Issue is about bladder cancer. Bladder cancer has become the ninth most common cancer worldwide, and the sixth most common malignancy in the United States, according to an epidemiologic statistics report published in 2017. Although many tumor markers associated with the development of bladder cancer have been widely reported, the rates of mortality and recurrence of bladder cancer are still high. Bladder cancer usually presents at an early stage, with most patients presenting with Tis or T1 disease and, thus, high recurrence rates. At present, different recurrence rates are observed according to the pathological staging and tumor grading. The reasons for this increase in recurrence, and tumor biology in particular, are poorly understood. Treatment of bladder cancer has evolved in recent years, with several new treatment techniques that lead to improvements in uro-oncology. This Special Issue mainly aims to discuss a collection of basic research and clinical treatments for the early detection, early diagnosis and early treatment of bladder cancer.
Here, we welcome papers outlining tumor biology, diagnostics, and treatment modalities of bladder cancer.
Prof. Dr. Ke-Hung Tsui
Prof. Dr. Horng-Heng Juang
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- bladder neoplasm
- tumor grading
- tumor staging